BridgeBio Pharma (NASDAQ: BBIO) revenue
BridgeBio Pharma reported revenue of $502.1m for fiscal 2025, 126.3% more than in fiscal 2024 ($221.9m). Since fiscal 2019 its revenue has grown by 1,137.9%, an average growth of 52.1% a year.
BridgeBio Pharma has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 7 fiscal years on record. The biggest drop was in fiscal 2023, −88.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $502.1m | +126.3% | −$523.4m | −104.2% |
| 2024 | $221.9m | +2,285.3% | −$593.0m | −267.2% |
| 2023 | $9.3m | −88.0% | −$607.4m | −6,528.8% |
| 2022 | $77.6m | +11.4% | −$512.2m | −659.6% |
| 2021 | $69.7m | +745.1% | −$576.6m | −827.1% |
| 2020 | $8.2m | −79.7% | −$474.5m | −5,752.0% |
| 2019 | $40.6m | — | −$266.2m | −656.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BridgeBio Pharma revenue compared with its sector
By revenue for its latest fiscal year, BridgeBio Pharma ranks 194th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; BridgeBio Pharma, 126.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 192nd | Glaukos | $507.4m | 32.3% |
| 193rd | STLN | $502.7m | 27.8% |
| 194th | BridgeBio Pharma | $502.1m | 126.3% |
| 195th | Travere Therapeutics | $490.7m | 110.5% |
| 196th | Phreesia | $480.6m | 14.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of BridgeBio Pharma
- How much revenue did BridgeBio Pharma make in fiscal 2025?
- BridgeBio Pharma reported revenue of $502.1m for fiscal 2025, compared with $221.9m in fiscal 2024.
- How much has the revenue of BridgeBio Pharma grown?
- Between fiscal 2019 and fiscal 2025 it went from $40.6m to $502.1m: 1,137.9% more, an average growth of 52.1% a year.
- What was the best year for revenue at BridgeBio Pharma?
- Of its last 7 fiscal years, fiscal 2025, with $502.1m.
- Where does BridgeBio Pharma rank in its sector by revenue?
- It ranks 194th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for BridgeBio Pharma come from?
- From the annual report (Form 10-K) that BridgeBio Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BridgeBio Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on BridgeBio Pharma: the BridgeBio Pharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.